Unexplained infertility Evidence based management

Similar documents
Infertility. Thomas Lloyd and Samera Dean

NICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic

Intrauterine (IUI) and Donor Insemination (DI) Policy (excluding In vitro fertilisation (IVF) & Intracytoplasmic sperm injection (ICSI) treatment)

Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary

Fertility in the 21 st Century Dr Leigh Searle

Fertility assessment and assisted conception

Biology of fertility control. Higher Human Biology

Infertility treatment

St Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16

Subfertility B Y A L I S O N, B E N A N D J O H N

Blackpool CCG. Policies for the Commissioning of Healthcare. Assisted Conception

Recent Developments in Infertility Treatment

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations

NaProTechnology. An Integrated Approach to Infertility. Tracy Parnell. Geneva 2005

Current Evidence On Infertility Treatment

Dr Manuela Toledo - Procedures in ART -

Clinical Policy Committee

Director of Commissioning, Telford and Wrekin CCG and Shropshire CCG. Version No. Approval Date August 2015 Review Date August 2017

Top 10 questions in fertility

ASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE

Fertility Assessment and Treatment Pathway

Note: This updated policy supersedes all previous fertility policies and reflects changes agreed by BHR CCGs governing bodies in June 2017.

Information Booklet. Exploring the causes of infertility and treatment options.

5/5/2010. Infertility FINANCIAL DISCLOSURE. Infertility Definition. Objectives. Normal Human Fertility. Normal Menstrual Cycle

Fertility Treatment: Do not be Distracted

Fertility. Assessment and treatment for people with fertility problems. Issued: February NICE clinical guideline 156. guidance.nice.org.

GPVTS TEACHING APRIL 2016 FERTILITY

Approved January Waltham Forest CCG Fertility policy

Assisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi

HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page

Clinical Policy Committee

Nandi, Arupa. For additional information about this publication click this link.

In vitro fertilisation for unexplained subfertility (Review)

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.

NHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs

Fertility Assessment and Treatment Pathway

Infertility: A Generalist s Perspective

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Interim Clinical Commissioning Policy: Assisted Conception. Agreed: September 2013 Reference: N-SC/037. England

Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)

Fertility Policy. December Introduction

Assisted Conception Policy

Chris Davies & Greg Handley

Dr Guy Gudex. Director Repromed. 17:00-17:30 Recent Advances in Fertility Management

The evidence for insemination versus intercourse or IVF

Appendix 1: Specialist Fertility Services Commissioning Policy

Infertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem?

COMMISSIONING POLICY. Tertiary treatment for assisted conception services

Is the fallopian tube better than the uterus? Evidence on intrauterine insemination versus fallopian sperm perfusion

Influence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser

Governing Body Meeting

Clinical guideline Published: 20 February 2013 nice.org.uk/guidance/cg156

Minimal Access Surgery in Gynaecology

Subfertility & prognostic factors & intrauterine insemination

Infertility treatment other than ART. Dr. Prue Johnstone FRANZCOG MRepMed

EDITOR S PICK INTRAUTERINE INSEMINATION: CURRENT PLACE IN INFERTILITY MANAGEMENT. *Shikha Jain

Commissioning Policy For In Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) within Tertiary Infertility Services

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme

Real lives. Real people. Real successes. Price List. Fertility treatment, gynaecology, male and female health care. Consultations.

Causes of Infertility and Treatment Options

Fertility treatment and referral criteria for tertiary level assisted conception

Bumiputera Sarawak Bumiputera Sabah. Others Foreigner. Had previous natural pregnancy Previous IVF pregnancies. IVF live births.

EVALUATING THE INFERTILE PATIENT-COUPLES. Stephen Thorn, MD

Intrauterine Insemination - FAQs Q. How Does Pregnancy Occur?

Real lives. Real people. Real successes. Price List. Fertility treatment, gynaecology, male and female health care. Consultations.

East and North Hertfordshire CCG. Fertility treatment and referral criteria for tertiary level assisted conception

2017 United HealthCare Services, Inc.

Fertility treatment and referral criteria for tertiary level assisted conception

Management of Female infertility Tim Chang

Recommended Interim Policy Statement 150: Assisted Conception Services

1 - Advanced clinical course for ART with Hands on

Fertility Issues Update. Dr Sarah Wakeman FRANZCOG, CREI, Medical Director, Fertility Associates Christchurch

Aims of this talk. Evaluation & investigation. Basic treatments/options including ovulation induction & Intra uterine Insemination

SHIP8 Clinical Commissioning Groups Priorities Committee (Southampton, Hampshire, Isle of Wight and Portsmouth CCGs)

Ivf day 6 estradiol level

Policy statement. Commissioning of Fertility treatments

NaProTechnology Natural Procreative Technology

This information explains the advice about assessment and treatment for people with fertility problems that is set out in NICE guideline CG156.

Independent Review of Assisted Reproductive Technologies

Brighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director

Infertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF

Clinical evaluation of infertility

IVF. NHS North West London CCGs

DRAFT Policy for Assisted Conception


Puerto Rico Fertility Center

PRETREATMENT ASSESSMENT & MANAGEMENT (MODULE 1 B) March, 2018

Optimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE

INFERTILITY CAUSES. Basic evaluation of the female

Phases of the Ovarian Cycle

Original Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2

Neil Goodman, MD, FACE

Policy statement. Fertility treatments. This policy is unchanged from the version approved by the CCG in July 2014.

Timing is everything. Ovulation Tracking. 3 Cycles bulk-billed

IN VITRO FERTILISATION (IVF)

Intra uterine insemination (IUI) Information for Patients and Partners

NORCOM COMMISSIONING POLICY

LOW RESPONDERS. Poor Ovarian Response, Por

Reproduction and Development. Female Reproductive System

Pre-Treatment (For all treatment types) Initial Consultation 120 Planning Consultation 150 Follow Up Consultation 75

Transcription:

Unexplained infertility Evidence based management Dr Mark Hamilton Consultant Gynaecologist NHS Grampian/University of Aberdeen m.hamilton@abdn.ac.uk www.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc

Unexplained infertility Evidence based management Dr Mark Hamilton Consultant Gynaecologist NHS Grampian/University of Aberdeen

The assessment of infertility The Paradigm 100 Are eggs available Are sperm available Can the gametes meet 80 60 % Pregnant 40 20 0 0 6 12 18 24 Months trying

Causes of Infertility (%) Unexplained Tubal Ovulation Male 0 10 20 30 40 Secondary Primary

Unexplained Infertility

Diagnoses in unexplained infertility Endocrine factors Abnormal follicle growth Sub-optimal progesterone secretion (luteal phase deficiency) Luteinised unruptured follicle syndrome Hypersecretion of LH Ovulatory hyperprolactinaemia Ovarian factors Zona pellucida antibodies Diminished ovarian reserve (ovarian ageing) Uterine/endometrial factors Congenital uterine abnormalities Submucous fibroids Abnormal uterine perfusion Altered cytokine expression and action Disturbed T cell and natural killer cell function Tubal factors Disturbed tubal function i.e. peristalsis, cilia Sub-optimal metabolic support of gametes and embryos Altered immune activity Peritoneal factors Mild endometriosis Occult infection Altered immune activity Genetic factors Gamete and embryo aneuploidy Poor embryo morphology, cleavage and blastocyst formation Sperm cervical mucus interaction Altered cervical mucus production Anti-sperm antibodies Psychogenic factors Inadequate coital function

The place of tubal assessment Is laparoscopy obsolete as a screening test? Effective alternatives? History Basic Ultrasound CAT screening HycoSy

Prognosis in unexplained infertility 100 Changing the Paradigm Natural chances vs Intervention 80 60 % Pregnant 40 20 0 0 6 12 18 24 Months trying

Prognosis in unexplained infertility 100 Variables to consider Age of female Duration of infertility Previous pregnancy 80 60 % Pregnant 40 20 0 0 6 12 18 24 Months trying

Prognosis in unexplained infertility Age of female Trends in clinics >35yrs doubled <30yrs halved Biological effects Oocyte/embryo quality Implications for treatment Reduced effectiveness % 35 30 25 20 15 10 5 0 Unexplained infertility vs age >35yrs >35yrs <35yrs <35yrs Primary Secondary Maheshwari et al 2008

Prognosis in unexplained infertility Variables to consider 90 80 Prognosis relevant to duration Normal Age of female Duration of infertility % pregnant 70 60 50 Short Previous pregnancy 40 Medium 30 20 Long 10 0 1 2 3 4 5 6 7 8 9 10 11 12 Months trying

Prognosis in unexplained infertility 90 80 70 Prognosis relevant to duration Normal Short % pregnant 60 50 40 30 Medium Dynamics of patient decision making 20 10 Long 0 1 2 3 4 5 6 7 8 9 10 11 12 Months trying

Patient concerns re age IVF OUTCOME OVARIAN RESERVE 40 % LBR 30 20 10 35 37 38 41 Age (yrs) HFEA + SART Age (yrs) Broer et al 2014

Models in unexplained infertility Age, Duration, Semen quality (Total motile sperm), Previous pregnancy, GP/specialist referral (Hunault 2004)

Models in unexplained infertility Age, Duration, Semen quality (Total motile sperm), Previous pregnancy, GP/specialist referral (Hunault 2004) + BMI, FSH level, Cycle length, Tubal pathology (Bensdorp 2017)

Prognosis in infertility: concept of nomogram Age of female partner Action line Duration of exposure to pregnancy Gurunath et al HR Update 17 575-588 (2011)

Management of unexplained infertility Spectrum of invasiveness No treatment Clomifene IUI SO/IUI IVF

Controlled ovarian stimulation (COS) Simple treatment (usually clomifene) Little monitoring Correction of subtle ovulatory dysfunction Multiple follicular growth

Intra-uterine insemination Widely accepted treatment Increased sperm density in upper reproductive tract Closer proximity to one or more eggs Increased potential for fertilisation With or without superovulation

In-vitro fertilisation Widely accepted treatment Bypasses potential reproductive problems Demonstrates fertilisation Essential for tubal and severe male infertility Live birth rate 20-30%

Interventions in unexplained infertility IUI Intercourse COS IVF Conventional eset Natural cycle Stimulated Unstimulated IUI I/C

Expectant management: Natural conception rates Follow up in observational studies Note 81% conceptions at 3 years follow-up 74% of these arising spontaneously Limited contribution from IVF Brandes et al, Human. Reprod. 2011

Randomised Controlled Trial Evidence The Scottish Unexplained Infertility Trial (SUIT) Clomifene n = 192 Expectant n = 193 6 months follow-up IUI n = 191

Expectant management 6 months follow-up The Scottish Unexplained Infertility Trial (SUIT) Expectant n = 193 33 (17%) 6 months follow-up

Expectant management vs Controlled Ovarian Stimulation Scottish Ux Inf Trial OR 0.77 95% CI: 0.44 1.36 Expectant Clomifene P value Odds ratio n = 193 n = 192 (95% CI) 33 (17%) 26 (14%) 0.37 0.77 (0.44, 1.36) Clomifene + hcg trigger OR 1.55 95% CI 0.58 4.60 Multiple pregnancy rates similar Other approaches to COS vs expectant: Clomifene + IUI HMG rfsh FSH hp No differences

Expectant management vs Natural cycle IUI (Live Birth Rate) Expectant IUI n = 193 n = 191 33 (17%) 43 (23%) Scottish Unexplained Infertility Trial data OR 1.60 95% CI 0.92 2.78 Multiple pregnancy rates similar Veltman-Verlhurst et al Cochrane Reviews 2016

Expectant management vs Natural cycle IUI (Live Birth Rate) OR 1.60 95% CI 0.92 2.78 Multiple pregnancy rates similar Veltman-Verlhurst et al Cochrane Reviews 2016

Expectant management vs COS + IUI (timed intercourse) OR 0.82 95% CI 0.45 1.49 LBR 20% (COS) LBR 24% (TI) No difference in multiple pregnancy rates Veltman-Verlhurst et al Cochrane Reviews 2016

Expectant management vs COS + IUI (timed intercourse) Recent data favours intervention Livebirth with COS + IUI OR 3.41 95% CI 1.71 6.79 Farquhar et al 2018

Expectant management vs COS + IUI (timed intercourse) BUT Farquhar et al 2018 31 livebirths: 23 from COS + IUI 8 without assistance before/between IUI cycles!

COS + timed intercourse vs COS + IUI Pregnancy Rate Live Birth Rate OR 1.69 95% CI 1.14 2.53 Trend in favour of IUI OR 1.59 95% CI 0.88 2.88 Veltman-Verlhurst et al Cochrane Reviews 2016

COS + IUI vs Natural cycle IUI OR 0.48 95% CI 0.29 0.82 Less chance of live birth with natural cycle IUI Veltman-Verlhurst et al Cochrane Reviews 2016 Multiple pregnancies: Limited data One trial reported 29% in SO + IUI vs 4% in IUI

Natural cycle IUI vs COS + timed intercourse Clomifene IUI n = 192 n = 191 26 (14%) 43 (23%) Scottish Unexplained Infertility Trial Data In favour of natural cycle IUI Veltman-Verlhurst et al Cochrane Reviews 2016

Natural cycle IUI vs COS + timed intercourse BUT No difference in trial between interventions vs expectant management Moderate prognosis patients Need for trial in poor prognosis? Veltman-Verlhurst et al Cochrane Reviews 2016

Natural cycle IUI vs IVF Little substantive comparative evidence Usual to consider that with prolonged infertility an intervention is demanded by patients Single trial: 41% pregnancy rate with IVF 26% pregnancy rate with IUI Sample size inadequate to draw conclusions

FASTT Trial Randomisation Conventional Fast track 1. CC + IUI (3 cycles) 1. CC + IUI (3 cycles) 2. FSH + IUI (3 cycles) 2. IVF (up to 6 cycles) 3. IVF (up to 6 cycles) Time to pregnancy Time to pregnancy shorter in accelerated arm Gonadotrophins added no value Pregnancy rate 20%/cycle in CC/IUI stage 25%/cycle at FSH/IUI stage 67%/cycle at IVF stage Multiple pregnancy rates in both arms 20%

1NeS Trial RCT: Poor prognosis couples: <30% Hunault score COS + IUI (6 cycles) IVF (eset) (3 cycles) IVF (natural cycle) 6 cycles

1NeS Trial Live births Controlled Ovarian Stimulation + IUI vs IVF (eset or Modified Natural Cycle) No differences Healthy child (47% vs 52% vs 43%) Multiple pregnancy rates low (5-7%) Bensdorp et al 2015

1NeS Trial Time to pregnancy No association between treatment outcome and: BMI Age Ethnicity Smoking status TMSC Tjon-Kon-Fat et al 2015 Bensdorp et al 2015

Societal Attitudes: Societal & Individual Plus ça change plus c est la même chose

Conclusions Unexplained infertility is relatively common Diagnosis may be increasing Prognosis rather than diagnosis dictates management Impact of female age and duration of infertility Correct identification of couples who need treatment Evidence base on interventions is improving but remains incomplete Need to avoid harm

Pragmatism Determine prognosis Good prognosis hands off Poor prognosis - consider intervention Clomifene not helpful IUI on its own not helpful COS + IUI may be helpful but care with multiple pregnancy IVF with eset comparable results and in good hands maintains pregnancy rates and keeps the multiples down